Loring Wolcott & Coolidge Fiduciary Advisors LLP MA Has $672,000 Stock Position in Gilead Sciences, Inc. (NASDAQ:GILD)

Loring Wolcott & Coolidge Fiduciary Advisors LLP MA trimmed its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 8.0% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 8,586 shares of the biopharmaceutical company’s stock after selling 750 shares during the period. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA’s holdings in Gilead Sciences were worth $672,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds also recently bought and sold shares of GILD. Global Retirement Partners LLC increased its position in Gilead Sciences by 10.3% in the 3rd quarter. Global Retirement Partners LLC now owns 4,753 shares of the biopharmaceutical company’s stock worth $355,000 after purchasing an additional 445 shares during the last quarter. PFG Advisors boosted its stake in shares of Gilead Sciences by 24.1% during the 3rd quarter. PFG Advisors now owns 3,361 shares of the biopharmaceutical company’s stock worth $252,000 after acquiring an additional 652 shares in the last quarter. Montecito Bank & Trust boosted its stake in shares of Gilead Sciences by 13.2% during the 3rd quarter. Montecito Bank & Trust now owns 6,602 shares of the biopharmaceutical company’s stock worth $495,000 after acquiring an additional 771 shares in the last quarter. Fifth Third Wealth Advisors LLC bought a new stake in shares of Gilead Sciences during the 3rd quarter worth about $370,000. Finally, 1900 Wealth Management LLC bought a new stake in shares of Gilead Sciences during the 3rd quarter worth about $363,000. 83.67% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Gilead Sciences

In other news, insider Merdad Parsey sold 2,000 shares of the stock in a transaction that occurred on Monday, April 1st. The stock was sold at an average price of $72.96, for a total value of $145,920.00. Following the completion of the transaction, the insider now directly owns 96,304 shares of the company’s stock, valued at approximately $7,026,339.84. The sale was disclosed in a legal filing with the SEC, which is available at this link. 0.29% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

Several research firms have recently issued reports on GILD. Cantor Fitzgerald decreased their price target on Gilead Sciences from $80.00 to $78.00 and set a “neutral” rating for the company in a research note on Wednesday, February 7th. Oppenheimer restated an “outperform” rating and set a $105.00 target price on shares of Gilead Sciences in a research note on Friday. StockNews.com downgraded Gilead Sciences from a “strong-buy” rating to a “buy” rating in a research note on Friday. UBS Group decreased their target price on Gilead Sciences from $81.00 to $75.00 and set a “neutral” rating for the company in a research note on Wednesday, April 17th. Finally, Mizuho decreased their target price on Gilead Sciences from $101.00 to $90.00 and set a “buy” rating for the company in a research note on Thursday, February 22nd. One research analyst has rated the stock with a sell rating, nine have assigned a hold rating and six have issued a buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $84.71.

Gilead Sciences Stock Performance

Shares of GILD stock traded up $0.27 during mid-day trading on Tuesday, reaching $67.22. The stock had a trading volume of 2,133,691 shares, compared to its average volume of 7,261,793. Gilead Sciences, Inc. has a one year low of $65.90 and a one year high of $87.86. The company has a quick ratio of 1.27, a current ratio of 1.43 and a debt-to-equity ratio of 1.08. The firm’s 50 day simple moving average is $71.81 and its 200 day simple moving average is $76.51. The firm has a market cap of $83.69 billion, a PE ratio of 14.88, a P/E/G ratio of 0.92 and a beta of 0.19.

Gilead Sciences (NASDAQ:GILD) last issued its earnings results on Tuesday, February 6th. The biopharmaceutical company reported $1.72 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.76 by ($0.04). Gilead Sciences had a return on equity of 38.85% and a net margin of 20.89%. The company had revenue of $7.12 billion during the quarter, compared to analyst estimates of $7.10 billion. During the same period in the previous year, the company posted $1.67 earnings per share. The company’s quarterly revenue was down 3.7% on a year-over-year basis. On average, analysts forecast that Gilead Sciences, Inc. will post 6.55 EPS for the current year.

Gilead Sciences Increases Dividend

The business also recently announced a quarterly dividend, which was paid on Thursday, March 28th. Stockholders of record on Friday, March 15th were issued a $0.77 dividend. The ex-dividend date of this dividend was Thursday, March 14th. This is a boost from Gilead Sciences’s previous quarterly dividend of $0.75. This represents a $3.08 dividend on an annualized basis and a dividend yield of 4.58%. Gilead Sciences’s dividend payout ratio is presently 68.44%.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.